Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Decnupaz Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentEmpire BluecrossPolicy CC-0304

    Decnupaz (pivekimab sunirine-pvzy) Coverage for BPDCN

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0304 alerts

    Get alerted when Policy CC-0304 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity review for Decnupaz (pivekimab sunirine-pvzy), with coverage available for individuals under 19 years of age or for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

    Policy Summary
    PayerEmpire Bluecross
    PolicyDecnupaz (pivekimab sunirine-pvzy) Coverage for BPDCN
    Policy CodePolicy CC-0304
    Change TypeNew policy
    Effective DateJul 28, 2026
    Last ReviewJun 8, 2026
    Next Review DateNot specified
    Key ActionEstablish that the individual is under 19 years of age or has a diagnosis of BPDCN for prior authorization or clinical review.
    SourceLink
    POLICY UPDATE CHANGES

    New clinical criteria were established for Decnupaz coverage.

    HCPCS codes C9399 and J9999 and ICD-10-CM code C86.40 were added for Decnupaz coding.

    2Alternative approval pathways
    BPDCNPrimary covered indication
    3Applicable billing and diagnosis codes
    Hepatotoxicity/VODBlack-box safety warning

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial coverage approval

    Requests may be approved if either of the following criteria is met:

    Approval criteria

    • Age criterion: Individual is under 19 years of age.under 19 years
    • Disease criterion: Individual has a diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN).diagnosis of BPDCN

    All other indications are not approved under this policy.

    Requests that do not meet either approval pathway—being under 19 years of age or having a diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN)—may not be approved.

    Initial Therapy Criteria

    Initial therapy approval

    Requests for Decnupaz (pivekimab sunirine-pvzy) may be approved if either of the following criteria is met:

    Initial approval pathways

    • Age pathway: Individual is under 19 years of age.under 19 years
    • BPDCN pathway: Individual has a diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN).diagnosis of BPDCN

    Coding Information

    HCPCSHCPCS
    C9399Unclassified drugs or biologicals [when specified as Decnupaz (pivekimab- sunirine-pvzy)]
    J9999Not otherwise classified, antineoplastic drugs [when specified as Decnupaz (pivekimab-sunirine-pvzy)]
    ICD-10 DiagnosisICD-10
    C86.40Blastic NK-cell lymphoma not having achieved remission [blastic plasmacytoid dendritic cell neoplasm (BPDCN)]

    Provider Actions

    Prior Authorization

    Establish age or BPDCN diagnosis

    For prior authorization or other clinical review, establish at least one approval pathway: the individual is under 19 years of age, or the individual has a diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

    • Document that the individual is under 19 years of age; or
    • Document a diagnosis of BPDCN.
    Denial Risk

    Avoid criteria-based denial

    Requests may not be approved when the individual is not under 19 years of age, does not have BPDCN, or the request is for any other indication.

    • The request must meet at least one approval pathway.
    • All other indications are not approved under this policy.

    Background

    Decnupaz (pivekimab sunirine-pvzy) is a CD123-directed antibody-drug conjugate used primarily to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive and rare malignancy involving the bone marrow and blood that may also affect the lymph nodes and skin and may present as or progress to acute leukemia. The drug targets CD123-expressing cells and delivers an agent that induces cell death. Decnupaz carries a black-box warning for hepatotoxicity, including hepatic veno-occlusive disease; liver tests and total bilirubin should be monitored before each dose, with dose delay for liver test elevation and discontinuation if veno-occlusive disease occurs.

    Definitions

    Complete Response (CR)
    DefinitionThe disappearance of all signs of cancer as a result of treatment.
    Also calledComplete remission.
    Important clarificationA complete response does not indicate that the cancer has been cured.
    Policy Summary
    PayerEmpire Bluecross
    PolicyDecnupaz (pivekimab sunirine-pvzy) Coverage for BPDCN
    Policy CodePolicy CC-0304
    Change TypeNew policy
    Effective DateJul 28, 2026
    Last ReviewJun 8, 2026
    Next Review DateNot specified
    Key ActionEstablish that the individual is under 19 years of age or has a diagnosis of BPDCN for prior authorization or clinical review.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaCoding InformationProvider ActionsBackgroundDefinitions